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Natural products are a rich resource for the development of
chemical probes, functional foods (nutraceuticals), and phar-
maceuticals.[1] The remarkable structural diversity of natural
product or biology-oriented compound libraries in particular
argues for their use in applications[1b,2] such as drug screen-
ings.[3]
Enzymes that can posttranslationally modify proteins or
nucleic acids are attractive drug targets and include kinases
and phosphatases,[4] methyltransferases[5] and acetyltransfer-
ases, and deacetylases.[6] Recently, histone-modifying
enzymes like the deacetylase sirtuin 1 (SIRT1) were sug-
gested as drug targets for treating a variety of age-related
disorders such as neuropathogenic diseases, metabolic dis-
eases, and cancer.[7] Compound screenings for SIRT1 modu-
lators have revealed promising enzymatic activators such as
the natural product resveratrol and the synthetic compound
SRT1720. However, these findings are still highly controver-
sial due to reported assay artifacts. The employed screening
assays were based on fluorescence-labeled peptide substrates
and resulted in the purported but artificial enzymatic
activation of SIRT1. These findings have misled many
researchers over the years.[8]
Besides the generation of artifacts as observed in SIRT1
assays, there is a second general drawback of fluorescence-
based assays which is broadly underestimated: Autofluores-
cence of compound libraries and in particular natural product
libraries interferes with widely applied optical analyses[9] such
as time-resolved fluorescence resonance energy transfer (TR-
FRET).[10]
By contrast, mass spectrometry (MS) represents an
attractive alternative as substrates are detected directly.
Peptides are ionized and detected according to their mass to
charge ratios (m/z).[11] For example, deacetylation of a sub-
strate peptide can be directly detected as a 42 Da mass peak
shift (Figure 1).
Electrospray ionization (ESI)[12] and matrix-assisted laser
desorption/ionization (MALDI)[13] MS have become widely
used techniques in basic biological research. ESI MS depends
on the injection of dissolved analytes, and washing steps are
required between sample injections to avoid cross-contami-
nation. This procedure can limit throughput in practice.
MALDI MS is based on the simple preparation of spatially
distinct spots on a metal plate, each spot containing analyte
and matrix molecules. Since many spots can be placed side by
side on one plate, the consecutive ionization of analyte spots
by a laser facilitates high-throughput detection with a reduced
risk of cross-contamination. Although quantification was
initially a challenging aspect in the context of MALDI MS,
many quantification approaches have been developed since
then, in particular for low complex samples.[14] In recent years
this has resulted in several novel quantification-based tech-
niques, for example in genetic diagnostics.[15] Moreover, the
easy maintenance and operation of MALDI mass spectrom-
eters makes this method attractive to non-experts in mass
spectrometry.
Based on MALDI MS we have developed and validated
a method for the high-throughput discovery of lead com-
pounds and the characterization of compounds that can
modify the deacetylase activity of SIRT1 (see the Supporting
Figure 1. Deacetylation and acetylation of peptide substrates by SIRT1
and p300, respectively. Both deacetylation and acetylation result in
a change in peptide mass of 42 Da, which can be observed in the
mass spectra.
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Information, Figure S1). Furthermore we have adopted the
assay principle for the reverse reaction, that is, acetylation by
the acetyltransferase p300.
We tested the activity of the aforementioned purported
SIRT1 activators resveratrol and SRT1720 by MALDI MS
using various peptide substrates, either with or without
fluorescence label. Consistent with recent studies using
radioactive labeling[8a,b] or HPLC,[8c] we observed that differ-
ent fluorescence labels produced diverging activation artifacts
while the unlabeled natural peptide showed no SIRT1
activation but even inhibition (Figure 2).
To optimize the procedure for screening we applied the
unlabeled histone H4 peptide as a well-known target of
SIRT1[16] in a concentration of 0.5 mm. This is well below the
Km value ((16 2) mm ; Figure S2) and makes it possible to
detect competitive inhibitors.[17] The degree of deacetylation
was set at about 40% (10 nm SIRT1, 30 min; Figure S3a) to
enable robust detection of inhibitor activity. The quality of the
assay was confirmed by a Z’-value[18] of 0.5 (Figure S4).
Moreover, we determined an IC50 value of (0.26 0.02) mm
for suramin, a known SIRT1 inhibitor, which is consistent
with the literature value of (0.297 0.01) mm,[19] and an IC50
value of (0.58 0.03) mm for EX-527, another described
SIRT1 inhibitor, which is also in the range of recently
reported data.[20] The accuracy of these values generated by
MALDI was additionally validated by ESI MS (Table S1).
To calculate enzyme kinetics and compound potencies,
exact quantification techniques are essential. Quantification
with MALDI MS has been used successfully for complex
peptide samples and other biological samples.[21] We achieved
the reliable quantification of acetylated and deacetylated
peptides by generating peptide “calibration curves” (CC) as
described in the Supporting Information, in which the
measured values are plotted versus the calculated values
(Figure 3 and Figure S5), and this was used to correct the
experimental data. For uniform sample detection we opti-
mized preparation conditions by applying a homogeneous
ultrathin layer (UTL).[22] A more detailed description and
a discussion of peptide quantification are provided in detail in
the Supporting Information.
Using the described assay principle we screened
a library of 5500 natural products[3a] for SIRT1
modulators. To increase the throughput we pooled
five compounds in each well and used 384-format
MALDI target plates. Pools containing potential hits
were retested as single compounds.While the reaction
and sample purification took about half an hour each,
in a single automated MS run of about two hours we
could detect the activity of more than 1000 com-
pounds.
Sample throughput can be further enhanced by
optimizing the compound pooling size using the
following group testing equation [Eq. (1)].[23]
f ðnÞ ¼ ð1pÞnð1=nÞ ð1Þ
Here p is the expected screening hit rate for a given
compound library and n is the total number of pooled
compounds. The optimal pool size is defined as the maximum
of the plotted curve. The observed screening hit rate for our
natural product library was 0.15% which results in an optimal
pool size of n= 26 (Figure S6). We successfully tested pools of
up to 30 compounds, which included suramin as positive
control (Figure S7). This makes it possible to screen more
than 10000 compounds in a few hours.
Our screening revealed eight SIRT1 inhibitors (natural
products 1–8 ; Table 1; Table S2), which were then tested for
cytotoxicity in cell culture (Figure S8). Toxic compounds were
excluded from further characterization. The IC50 values of the
remaining five inhibitors were between 9.7 mm and 49 mm
(Table 1). SIRT1 inhibitors with such potency can have
valuable biological effects.[24]
We thus tested the strongest inhibitor, 1 (Figure 4a), for
its ability to increase p53 acetylation in human liver (HepG2)
cells. Cells were treated for 16 h with 30 mm 1. We observed
a significant increase of p53 acetylation in the nuclear fraction
by densitometric Western Blot analysis (Figure 4b).
We also used the described assay principle for the reverse
reaction: acetylation of a substrate peptide by the acetyl-
transferase p300. Assay conditions were set at 0.5 mm of a p53-
derived substrate peptide (HAT-peptide: STSRHKKL) and
a degree of acetylation of about 35% (250 nm p300, 60 min;
Figure S3b) was chosen, such that either inhibition or
activation of the enzyme could be detected.
Figure 2. Comparison of SIRT1 activators by using different substrate peptides
and MALDI detection. Substrates were fluorescently labeled and unlabeled
peptides. Reactions contained 1% DMSO, treatments 100 mm resveratrol (RSV)
and 100 mm SRT1720, respectively.
Figure 3. Peptide “calibration curve” depicts the relationship of the
measured peptide ratios to the calculated values and can be used to
interpolate measured sample values. 12 MALDI measurements were
conducted per data point.
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We thereby discovered a novel p300 inhibitor (9 ; Fig-
ure 5a; Table S2) and determined its IC50 value to be (1.71
0.07) mm (Figure 5b). We confirmed this value by applying
a radioactivity-based assay ((2.1 0.4) mm). The quercetin
derivative 9 is about 4 times stronger than anacardic acid
(IC50= 8.5 mm), which is found in the shells of cashew nuts,
[25]
and about 3.5 times stronger than garcinol (IC50= 7 mm),
which was found in the fruit rind of a tropical evergreen
tree.[26] It is furthermore about 17 times stronger than
quercetin, the core structure of 9, which also inhibits p300[27]
but only showed an IC50 around 34 mm in the radioactivity-
based assay. In cell culture, 9 displayed significant anti-
inflammatory effects by reducing the levels of TNFa secreted
by THP-1 cells (Figure S10). This is an interesting feature of
p300 inhibitors, which was recently shown for the p300
inhibitor curcumin.[28]
The natural products described in this study may become
valuable tools in the area of epigenetics and could in
particular be used to shed more light on the role of histone
deacetylases such as SIRT1 and acetyltransferases like p300 in
various biological processes. Further in-depth studies are
needed to explore their pharmacological profiles and poten-
tial health beneficial effects.
We have presented a straightforward MALDI MS based
method for the unbiased screening and characterization of
compounds that modify protein activity. Using this procedure










[a] Structures were generated by using the program ChemDraw Ultra 9.0.
[b] n.d.: not determined.
Figure 4. a) IC50 curve for 1 and SIRT1 generated by MALDI quantifica-
tion using H4 peptide (SGRGKGGKGLGKGGA-K(Ac)-RHRK). b) Densi-
tometric analysis of the Western blot data showing the effect of
treating HepG2 cells with 30 mm 1 for 16 h on the acetylation state of
p53 (Lys382) in the nuclear cell fraction (raw data: Figure S9). Basic
p53 acetylation was induced by simultaneous treatment with 20 mm
Etoposide (Eto).
Figure 5. a) Structure of the new p300 inhibitor 9. b) IC50 curve for 9
and p300 generated by MALDI quantification.
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we could circumvent analytical problems deriving from
compounds with autofluorescence. Clearly, a large variety of
posttranslationally active enzymes like deacetylases, acetyl-
transferases, kinases, phosphatases, and methyltransferases
can be studied in the presented way using appropriate
substrate peptides and assay conditions.
Received: September 11, 2012
Revised: December 12, 2012
Published online: April 8, 2013
.Keywords: compound screening · enzymes · MALDI ·
mass spectrometry · natural products
[1] a) M. Mller, S. Kersten, Nat. Rev. Genet. 2003, 4, 315 – 322;
b) K. S. Lam, Trends Microbiol. 2007, 15, 279 – 289; c) J. Hong,
Curr. Opin. Chem. Biol. 2011, 15, 350 – 354; d) E. Zamir, P. I.
Bastiaens, Nat. Chem. Biol. 2008, 4, 643 – 647; e) J. W. Li, J. C.
Vederas, Science 2009, 325, 161 – 165.
[2] S. Wetzel, R. S. Bon, K. Kumar, H. Waldmann, Angew. Chem.
2011, 123, 10990 – 11018;Angew. Chem. Int. Ed. 2011, 50, 10800 –
10826.
[3] a) C. Weidner, J. C. de Groot, A. Prasad, A. Freiwald, C.
Quedenau, M. Kliem, A. Witzke, V. Kodelja, C. T. Han, S.
Giegold, M. Baumann, B. Klebl, K. Siems, L. Muller-Kuhrt, A.
Schurmann, R. Schuler, A. F. Pfeiffer, F. C. Schroeder, K.
Bussow, S. Sauer, Proc. Natl. Acad. Sci. USA 2012, 109, 7257 –
7262; b) E. Mazzio, S. Deiab, K. Park, K. Soliman, Phytother.
Res. 2012, ahead of print, DOI: 10.1002/ptr.4795; c) W. Min, W.
Wang, J. Chen, A. Wang, Z. Hu,Anal. Bioanal. Chem. 2012, 404,
2397 – 2405.
[4] L. K. Nguyen, D. Matallanas, D. R. Croucher, A. von Krieg-
sheim, B. N. Kholodenko, FEBS J. 2013, 279, 751 – 765.
[5] R. Teperino, K. Schoonjans, J. Auwerx, Cell Metab. 2010, 12,
321 – 327.
[6] A. Peserico, C. Simone, J. Biomed. Biotechnol. 2011, 371832.
[7] a) K. Huber, G. Superti-Furga, Bioorg. Med. Chem. 2011, 19,
3616 – 3624; b) S. Lavu, O. Boss, P. J. Elliott, P. D. Lambert, Nat.
Rev. Drug Discovery 2008, 7, 841 – 853.
[8] a) M. Kaeberlein, T. McDonagh, B. Heltweg, J. Hixon, E. A.
Westman, S. D. Caldwell, A. Napper, R. Curtis, P. S. DiStefano,
S. Fields, A. Bedalov, B. K. Kennedy, J. Biol. Chem. 2005, 280,
17038 – 17045; b) M. T. Borra, B. C. Smith, J. M. Denu, J. Biol.
Chem. 2005, 280, 17187 – 17195; c) M. Pacholec, J. E. Bleasdale,
B. Chrunyk, D. Cunningham, D. Flynn, R. S. Garofalo, D.
Griffith, M. Griffor, P. Loulakis, B. Pabst, X. Qiu, B. Stockman,
V. Thanabal, A. Varghese, J. Ward, J. Withka, K. Ahn, J. Biol.
Chem. 2010, 285, 8340 – 8351; d) D. Beher, J. Wu, S. Cumine,
K. W. Kim, S. C. Lu, L. Atangan, M. Wang, Chem. Biol. Drug
Des. 2009, 74, 619 – 624.
[9] N. Thorne, D. S. Auld, J. Inglese, Curr. Opin. Chem. Biol. 2010,
14, 315 – 324.
[10] a) C. M. Yengo, C. L. Berger, Curr. Opin. Pharmacol. 2010, 10,
731 – 737; b) W. A. Lea, A. Simeonov, Expert Opin. Drug
Discovery 2011, 6, 17 – 32.
[11] S. Sauer, M. Kliem, Nat. Rev. Microbiol. 2010, 8, 74 – 82.
[12] J. B. Fenn, Angew. Chem. 2003, 115, 3999 – 4024; Angew. Chem.
Int. Ed. 2003, 42, 3871 – 3894.
[13] M. Karas, F. Hillenkamp, Anal. Chem. 1988, 60, 2299 – 2301.
[14] a) M. W. Duncan, H. Roder, S. W. Hunsucker, Briefings Funct.
Genomics Proteomics 2008, 7, 355 – 370; b) H. Matsumoto, E. S.
Kahn, N. Komori, Anal. Biochem. 1998, 260, 188 – 194.
[15] a) M. Ehrich, M. R. Nelson, P. Stanssens, M. Zabeau, T.
Liloglou, G. Xinarianos, C. R. Cantor, J. K. Field, D. van den
Boom, Proc. Natl. Acad. Sci. USA 2005, 102, 15785 – 15790;
b) Y. M. Lo, N. B. Tsui, R. W. Chiu, T. K. Lau, T. N. Leung,
M. M. Heung, A. Gerovassili, Y. Jin, K. H. Nicolaides, C. R.
Cantor, C. Ding, Nat. Med. 2007, 13, 218 – 223.
[16] A. Vaquero, R. Sternglanz, D. Reinberg, Oncogene 2007, 26,
5505 – 5520.
[17] G. Wu, Y. Yuan, C. N. Hodge, J. Biomol. Screening 2003, 8, 694 –
700.
[18] J. H. Zhang, T. D. Chung, K. R. Oldenburg, J. Biomol. Screening
1999, 4, 67 – 73.
[19] J. Trapp, R. Meier, D. Hongwiset, M. U. Kassack, W. Sippl, M.
Jung, ChemMedChem 2007, 2, 1419 – 1431.
[20] A. D. Napper, J. Hixon, T. McDonagh, K. Keavey, J. F. Pons, J.
Barker, W. T. Yau, P. Amouzegh, A. Flegg, E. Hamelin, R. J.
Thomas, M. Kates, S. Jones, M. A. Navia, J. O. Saunders, P. S.
DiStefano, R. Curtis, J. Med. Chem. 2005, 48, 8045 – 8054.
[21] a) J. Gobom, K. O. Kraeuter, R. Persson, H. Steen, P. Roepstorff,
R. Ekman, Anal. Chem. 2000, 72, 3320 – 3326; b) J. L. Hsu, S. Y.
Huang, N. H. Chow, S. H. Chen, Anal. Chem. 2003, 75, 6843 –
6852; c) S. Sauer, Clin. Chim. Acta 2006, 363, 95 – 105; d) A.
Cullinan, C. Cantor, Pharmacogenomics 2008, 9, 1211 – 1215.
[22] a) S. Sauer, J. Biochem. Biophys. Methods 2007, 70, 311 – 318;
b) D. Fenyo, Q. Wang, J. A. DeGrasse, J. C. Padovan, M.
Cadene, B. T. Chait, J. Visualized Exp. 2007, 192.
[23] L. Sachs, Angewandte Statistik – Anwendung statistischer
Methoden, Vol. 11, berarbeitete und aktualisierte Auflage,
Springer, Berlin, 2004, pp. 261 – 262.
[24] C. Gey, S. Kyrylenko, L. Hennig, L. H. Nguyen, A. Buttner,
H. D. Pham, A. Giannis, Angew. Chem. 2007, 119, 5311 – 5314;
Angew. Chem. Int. Ed. 2007, 46, 5219 – 5222.
[25] K. Balasubramanyam, V. Swaminathan, A. Ranganathan, T. K.
Kundu, J. Biol. Chem. 2003, 278, 19134 – 19140.
[26] K. Balasubramanyam, M. Altaf, R. A. Varier, V. Swaminathan,
A. Ravindran, P. P. Sadhale, T. K. Kundu, J. Biol. Chem. 2004,
279, 33716 – 33726.
[27] X. Xiao, D. Shi, L. Liu, J. Wang, X. Xie, T. Kang, W. Deng, PLoS
One 2011, 6, e22934.




5174 www.angewandte.org  2013 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Angew. Chem. Int. Ed. 2013, 52, 5171 –5174
